MindWalk Holdings, Inc. (HYFT): Debt to Book Capitalization Ratio

Corporate company logo of MindWalk Holdings, Inc. (HYFT)

MindWalk Holdings (HYFT) is developing personalized therapies through iPath and partnerships with diagnostic providers. This chart on GURU.Markets illustrates the total debt-to-equity ratio, where 0.47 indicates the current level. The company creates AI algorithms for biopharmaceuticals, accelerating drug discovery. Corporate data automation ensures margin scalability and reduces operating expenses.

HYFT MindWalk Therapeutics: Debt to Book Value in the range 09/05/2025 - 10/30/2026
Manufactured products of MindWalk

To assess the issuer's financial stability, it is critical to analyze the ratio of total liabilities to the market value of equity. This coefficient measures the degree of debt load and the company's sensitivity to rising borrowing costs. For MindWalk Holdings (HYFT), with its scalable, capex-free AI model, a low leverage level confirms the efficiency of its API integrations. By analyzing changes in the proportion of total debt to book capitalization, an investor determines the risk of default or the inefficiency of capital utilization.

Competing companies

Debts to Book Capitalization HLN (Haleon plc)|Debts to Book Capitalization kenvue.com KVUE|VRNA - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio MENS (Jyong Biotech Limited)|Ligand Pharma (LGND) - Debt to Book Capitalization Ratio|Debt to Book Value Amneal Corp|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com|Debt to Book Value LQDA (Liquidia)|GLPG (Galapagos N.V.) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ANI Pharma ANIP|Afrezza (MNKD) - Debts to Book Value|AMPH: Debt to Book Value|pacira.com - Debt to Book Capital|SPRY: Debts to Book Capitalization|Theravance Biopharma Inc - Debt to Net Assets Ratio|AQST (Aquestive Pharma) - Debts to Book Capitalization|Debts to Book Value scPharma SCPH|Debt to Book Capitalization Ratio Tectonic Therapeutic, Inc. (TECX)|TNXP (tonixpharma.com) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio China SXT Pharmaceuticals, Inc. SXTC|EPRX - Debt to Book Value|BioHarvest - Debts to Book Capitalization|Debts to Net Assets Invizyne EXOZ|oramed.com (ORMP) - Debt to Book Capitalization Ratio|Debt to Book Value Ratio ENTX|ABVC (ABVC BioPharma, Inc.) - Debts to Book Capitalization|Debt to Book Value Ratio CPIX (Cumberland Pharmaceuticals Inc)|Debt to Book Value QNTM (Quantum BioPharma Limited)|Debt to Book Value FibroGen Corporation FGEN|Debts to Book Capitalization TELO (Telomir Pharmaceuticals)|Debts to Book Capitalization Rani Therapeutics Holdings RANI|SNYR - Debt to Book Capitalization Ratio|RLYB: Debt to Book Capitalization Ratio|lexariabioscience.com (LEXX) - Debt to Book Capitalization Ratio|Pulmatrix Corporation (PULM) - Debts to Book Capitalization|Debt to Book Value PTHL|APM: Debt to Net Assets Ratio|Debts to Book Capitalization LYRA|IBO (Impact BioMedical, Inc.) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio TNF Pharmaceuticals, Inc. TNFA|cbdMD Inc. (YCBD) - Debts to Book Value|PRFX - Debt to Book Capitalization Ratio|CYTO: Debt to Book Capitalization Ratio|LIPO: Debts to Book Capitalization|Debt to Book Value Ratio OPTN|PIRS (Pieris) - Debts to Book Capitalization|Procaps Group Corp (PROC) - Debts to Net Assets|Debt to Book Capitalization Ratio Petros Pharmaceuticals (PTPI)|qlsyy.net - Debt to Book Value Ratio|Debts to Book Capitalization SLRN (ACELYRIN)|Debt to Net Assets TFF Pharmaceuticals Inc.